AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.45−0.17 (-3.02%)
Close on Nov 20, 2026Market cap $136.25KP/E –Yield –
AgomAb Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
No free cash flow figures for AgomAb Therapeutics
AgomAb Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?